40
Participants
Start Date
March 31, 2002
Primary Completion Date
September 30, 2007
Study Completion Date
January 31, 2011
Gemcitabine, Etoposide
Pancreatic cancer is a devastating disease. Previous research shows a correlation between a specific oncogene change (ras-mutation) and enhanced sensitivity to two chemotherapy drugs combined: gemcitabine and etoposide. This Phase II trial will evaluate this drug combination for locally advanced and metastatic pancreatic cancer
Grand Rapids Clinical Oncology Program, Grand Rapids
Collaborators (1)
Van Andel Research Institute
OTHER
Eli Lilly and Company
INDUSTRY
Battle Creek Health System
OTHER
Mercy Health System
NETWORK
Metropolitan Hospital, Michigan
OTHER
Mecosta County General Hospital
UNKNOWN
Munson Medical Center
OTHER
Saint Mary's Health Network
OTHER
Spectrum Health Hospitals
OTHER